Business Context and Reporting Period
This Form 8-K is a current report filed by Supernus Pharmaceuticals, Inc. on April 22, 2024. The filing addresses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- John M. Siebert, Ph.D. has decided to retire from the Company's Board of Directors.
- The retirement is effective at the Company's Annual Meeting of Stockholders in June 2024.
- Mr. Siebert is not standing for re-election.
- The departure is not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The Board expressed appreciation for Mr. Siebert's more than a decade of dedicated service.
Investor Verification Checklist
- Confirm the date of the Annual Meeting of Stockholders in June 2024 to verify the effective date of the retirement.
- Review the Company's proxy statement for the Annual Meeting to see if a replacement director is being nominated.
- Verify the composition of the Board of Directors following the Annual Meeting.